PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25310209-6	2014	The diagnosis of BPDCN is based on the characteristic cytology and immunophenotype of malignant cells coexpressing CD4, CD56, CD123, blood dendritic cell antigens 2 and 4, and CD2AP markers.	bpdcn	17-22	neural cell adhesion molecule 1	Homo sapiens	120-124	
25779340-8	2015	However, we demonstrated that BPDCN is closer to CD56(+) DCs than pDCs by global gene-expression profiling.	bpdcn	30-35	neural cell adhesion molecule 1	Homo sapiens	49-53	
23940084-8	2013	In conclusion, BPDCN in the bone marrow has a characteristic immunoprofile (CD4+, CD56+, CD123+, and TCL-1+) and appears to be commonly associated with myelodysplastic features and a high frequency of TET2 mutations in the absence of other mutations commonly observed in AML.	bpdcn	15-20	neural cell adhesion molecule 1	Homo sapiens	82-86	
25120824-7	2014	According to skin biopsy, the tumor cells reveal an immature blastic appearance and positive for CD4 and CD56, negative for CD3, CD20, indicating a diagnosis of BPDCN.	bpdcn	161-166	neural cell adhesion molecule 1	Homo sapiens	105-109	
24390220-7	2014	BPDCN was associated with positive staining for CD56, TdT, or TCL1, or negative staining for lysozyme.	bpdcn	0-5	neural cell adhesion molecule 1	Homo sapiens	48-52	
22241735-9	2013	BPDCN should be strongly considered during the differential diagnosis of CD56-positive neoplasms of the skin.	bpdcn	0-5	neural cell adhesion molecule 1	Homo sapiens	73-77	
24312342-3	2013	However, BPDCN can be distinguished from pDCs by uniform expression of CD56.	bpdcn	9-14	neural cell adhesion molecule 1	Homo sapiens	71-75	
21701157-2	2011	We present a case of an 80-year-old man with a CD4+CD56+ BPDCN that affected the orbital cavity and bone marrow.	bpdcn	57-62	neural cell adhesion molecule 1	Homo sapiens	51-55	
22915052-3	2012	Flow cytometry study identified a cell population CD4+/CD56+/CD45RA+/CD123+/TCL1+ suggestive of BPDCN diagnosis, which was confirmed by a lymph node biopsy (cells positive for BCL11a, BDCA-2, CD2AP, CD123, TCL1 and S100).	bpdcn	96-101	neural cell adhesion molecule 1	Homo sapiens	55-59	
19793612-5	2010	Immunophenotyping of typical BPDCN cases revealed CD4(+), CD56(+), HLA-DR(+) and CD123(bright) neoplastic cells, in the absence of major B-, T- and myeloid-associated markers, while the phenotype of the four cases characterized as LAL highlights the risk of misdiagnosis.	bpdcn	29-34	neural cell adhesion molecule 1	Homo sapiens	58-62	
29660158-6	2018	Here, we report the case of a 61-year-old woman who presented with an AML with MLL rearrangement and CD4+/CD56+ expression presenting as LC and that was misdiagnosed as BPDCN.	bpdcn	169-174	neural cell adhesion molecule 1	Homo sapiens	106-110	
32241840-9	2021	In summary, by understanding the immunophenotype of reactive and neoplastic PDCs, BPDCN can be effectively detected by flow cytometry to a very low level using a panel of markers in addition to CD56, and such assay can be used for initial bone marrow workup as well as MRD detection after therapy.	bpdcn	82-87	neural cell adhesion molecule 1	Homo sapiens	194-198	
35171796-8	2022	Immunohistochemically, CD4, CD56, CD123 and TCL-1 were positive in 82.1%, 92.9%, 96.0% and 100% cases of BPDCN, respectively.	bpdcn	105-110	neural cell adhesion molecule 1	Homo sapiens	28-32	
27913457-4	2016	BPDCN is most easily defined by the phenotype CD4+CD56+CD123+lineage-MPO-, although many patients will present with variable expression of CD4, CD56, or alternate plasmacytoid markers, which compounds the difficulty in differentiating BPDCN from other myeloid or lymphoid malignancies.	bpdcn	0-5	neural cell adhesion molecule 1	Homo sapiens	50-54